Tags : Dova Pharmaceuticals


PharmaShots’ Key Highlights of Third Quarter 2019

The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer’s Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired […]Read More


Sobi to Acquire Dova Pharmaceuticals for $915M

Shots: Sobi acquires Dova Pharmaceutical in cash & stock transaction making a total deal value as $915M.  Dova to receive upfront of $27.50/share in cash, $1.50/share on approval of Doptelet as CVR, representing a total consideration of up to $29.00/share with a premium of 36% to Dova’s closing price on Sept 27, 2019 The focus […]Read More